Chennai, India — The Tamil Nadu government has swiftly enacted a ban on the sale and distribution of Coldrif cough syrup following alarming reports linking the medication to the deaths of several children in neighboring states. The decision comes in the wake of the tragic loss of 11 young lives—nine in Madhya Pradesh and two in Rajasthan—suspected to be caused by the cough syrup.
Health officials in Madhya Pradesh reported that post-mortem analyses revealed the presence of Diethylene Glycol (DEG), a highly toxic substance, in the kidney tissues of the deceased children. This chemical is known to cause acute renal failure, raising serious concerns about the safety of the syrup, manufactured by Sresan Pharmaceuticals in Kancheepuram district.
The Tamil Nadu Drugs Control department received a formal notification from Madhya Pradesh’s drug regulatory authority, prompting immediate action against Coldrif. S. Gurubharathi, Deputy Director of Drugs Control, stated that drug inspectors have been instructed to remove all stock from retail shelves and halt further sales of the product until a thorough investigation is completed.
Preliminary investigations suggest that the batch of cough syrup under scrutiny may have been distributed beyond Tamil Nadu, potentially reaching markets in Puducherry and Odisha. Officials have alerted neighboring states to ensure that similar precautions are taken to safeguard public health.
Authorities are currently conducting rigorous testing on samples of Coldrif and additional formulations from Sresan Pharmaceuticals. The ban remains in effect until laboratory results confirm the product’s safety for consumers. “We are prioritizing public safety and will take all necessary measures to prevent any further incidents,” Gurubharathi emphasized.
This incident underscores the critical need for stringent quality control in the pharmaceutical industry, particularly for medications that are widely used among vulnerable populations, such as children. Ongoing investigations aim to determine how the toxic substance ended up in the cough syrup and what measures can be implemented to prevent future occurrences.
As families mourn the loss of their children, the incident has sparked widespread outrage and demands for accountability from pharmaceutical manufacturers. The Tamil Nadu government has assured the public that thorough scrutiny will be applied not only to Coldrif but also to other products that may pose health risks.
Officials continue to monitor the situation closely and are urging parents and caregivers to report any adverse effects from medicinal products. The focus remains on restoring trust in public health safeguards and ensuring that such tragedies do not repeat themselves.